22nd Century Presents at Hofstra Northwell School of Medicine; Reveals New Initiative to Engage Health Care Professionals

CLARENCE, N.Y.–(BUSINESS WIRE)–22nd Century Group, Inc. (NYSE MKT: XXII),
a plant biotechnology company that is a leader in tobacco harm
reduction, announced today that on May 26, 2016, Paul J. Rushton, Ph.D.,
the Company’s Vice President of Plant Biotechnology, gave a seminar to
discuss 22nd Century’s novel Very Low Nicotine smoking cessation aid at
Hofstra Northwell School of Medicine on the campus of Hofstra University
in Hempstead, New York.
During the presentation, Dr. Rushton announced a new initiative to
engage medical departments, medical professionals, and professors at
prominent U.S. medical schools as part of a new effort by 22nd Century
to inform health care professionals about the Company’s Very Low
Nicotine products and their potential to revolutionize the options
available for doctors to treat smoking addiction.
Dr. Rushton explained: “We are now in the regulatory and education
phases for our Very Low Nicotine products as 22nd Century’s Very Low
Nicotine cigarettes are currently under review with the FDA to become
the first-ever Modified Risk Tobacco Product (MRTP), MAGIC 0 Very Low
Nicotine cigarettes are launching in Europe and in Australia, and we are
planning Phase III clinical trials for our ‘X-22’ prescription
smoking cessation aid in development. Moving forward, of critical
importance is introducing our products to medical professionals who
treat patients and prescribe therapies to help their patients quit
smoking.”
In other news, 22nd Century will make presentations at both the 2016
Marcum MicroCap Conference in New York City and the 6th Annual LD Micro
Invitational in Los Angeles:
2016 Marcum MicroCap Conference
Location: Grand Hyatt, 109
East 42nd St, New York, NY 10017
22nd Century Presentation Date:
June 1, 2016
6th Annual LD Micro Invitational
Location: Luxe Sunset Blvd
Hotel, 11461 Sunset Blvd, Los Angeles, CA 90049
22nd Century
Presentation Date: June 8, 2016
Both by-invitation-only investor conferences focus on promising,
undervalued companies in the microcap space. Henry Sicignano, III,
President and Chief Executive Officer of 22nd Century Group, will
deliver a formal presentation at each conference on the respective dates
noted above. In addition, Mr. Sicignano will be available for one-on-one
investor meetings at both conferences.
To arrange a one-on-one meeting with 22nd Century, please contact Andrew
Haag at xxii@irthcommunications.com
or 1-866-976-4784.
About 22nd Century Group, Inc.
22nd Century is a plant biotechnology company focused on technology
which allows it to increase or decrease the level of nicotine in tobacco
plants and the level of cannabinoids in cannabis plants through genetic
engineering and plant breeding. The Company’s primary mission is to
reduce the harm caused by smoking. 22nd Century currently owns or
exclusively controls more than 200 issued patents and more than 50
pending patent applications around the world. Visit www.xxiicentury.com
for more information.
Cautionary Note Regarding Forward-Looking Statements:This
press release contains forward-looking information, including all
statements that are not statements of historical fact regarding the
intent, belief or current expectations of 22nd Century Group, Inc., its
directors or its officers with respect to the contents of this press
release, including but not limited to our future revenue expectations.
The words “may,” “would,” “will,” “expect,” “estimate,” “anticipate,”
“believe,” “intend” and similar expressions and variations thereof are
intended to identify forward-looking statements. We cannot guarantee
future results, levels of activity or performance. You should not place
undue reliance on these forward-looking statements, which speak only as
of the date that they were made. These cautionary statements should be
considered with any written or oral forward-looking statements that we
may issue in the future. Except as required by applicable law, including
the securities laws of the United States, we do not intend to update any
of the forward-looking statements to conform these statements to reflect
actual results, later events or circumstances, or to reflect the
occurrence of unanticipated events. You should carefully review and
consider the various disclosures made by us in our annual report on Form
10-K for the fiscal year ended December 31, 2015, filed on February 18,
2016, including the section entitled “Risk Factors,” and our other
reports filed with the U.S. Securities and Exchange Commission which
attempt to advise interested parties of the risks and factors that may
affect our business, financial condition, results of operation and cash
flows. If one or more of these risks or uncertainties materialize, or if
the underlying assumptions prove incorrect, our actual results may vary
materially from those expected or projected.